<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28935773</article-id><article-id pub-id-type="pmc">5728028</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2017-0066</article-id><article-id pub-id-type="publisher-id">ONCO12239</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>5</subject><subject>31</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial</article-title></title-group><contrib-group><contrib id="onco12239-cr-0001" contrib-type="author" corresp="yes"><name><surname>Ko</surname><given-names>Andrew H.</given-names></name><address><email>andrew.ko@ucsf.edu</email></address><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="onco12239-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12239-cr-0002" contrib-type="author"><name><surname>Murphy</surname><given-names>Patrick B.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12239-cr-0003" contrib-type="author"><name><surname>Peyton</surname><given-names>James D.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12239-cr-0004" contrib-type="author"><name><surname>Shipley</surname><given-names>Dianna L.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12239-cr-0005" contrib-type="author"><name><surname>Al‐Hazzouri</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="onco12239-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12239-cr-0006" contrib-type="author"><name><surname>Rodriguez</surname><given-names>Francisco A.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12239-cr-0007" contrib-type="author"><name><surname>Womack</surname><given-names>Mark S.</given-names><suffix>IV</suffix></name><xref ref-type="aff" rid="onco12239-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12239-cr-0008" contrib-type="author"><name><surname>Xiong</surname><given-names>Henry Q.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12239-cr-0009" contrib-type="author"><name><surname>Waterhouse</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0006"><sup>f</sup></xref></contrib><contrib id="onco12239-cr-00010" contrib-type="author"><name><surname>Tempero</surname><given-names>Margaret A.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12239-cr-00011" contrib-type="author"><name><surname>Guo</surname><given-names>Shuangli</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12239-cr-00012" contrib-type="author"><name><surname>Lane</surname><given-names>Cassie M.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12239-cr-00013" contrib-type="author"><name><surname>Earwood</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12239-cr-00014" contrib-type="author"><name><surname>DeBusk</surname><given-names>Laura M.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12239-cr-00015" contrib-type="author"><name><surname>Bendell</surname><given-names>Johanna C.</given-names></name><xref ref-type="aff" rid="onco12239-aff-0007"><sup>g</sup></xref></contrib><aff id="onco12239-aff-0001"><label><sup>a</sup></label>
<institution>Division of Hematology and Oncology, University of California</institution>, <city>San Francisco</city>, <state>California</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0002"><label><sup>b</sup></label>
<institution>Tennessee Oncology, PLLC/SCRI</institution>, <city>Nashville</city>, <state>Tennessee</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0003"><label><sup>c</sup></label><institution>Florida Cancer Specialists/SCRI</institution>, <city>Fort Myers</city>, <state>Florida</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0004"><label><sup>d</sup></label>
<institution>Tennessee Oncology, PLLC/SCRI</institution>, <city>Chattanooga</city>, <state>Tennessee</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0005"><label><sup>e</sup></label><institution>The Center for Cancer and Blood Disorders/SCRI</institution>, <city>Fort Worth</city>, <state>Texas</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0006"><label><sup>f</sup></label><institution>Oncology Hematology Care/SCRI</institution>, <city>Cincinnati</city>, <state>Ohio</state>, <country country="US">USA</country>
</aff><aff id="onco12239-aff-0007"><label><sup>g</sup></label><institution>Sarah Cannon Research Institute (SCRI)</institution>, <city>Nashville</city>, <state>Tennessee</state>, <country country="US">USA</country>
</aff></contrib-group><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: Andrew Ko, M.D., Division of Hematology and Oncology, University of California, San Francisco, 550 16th Street, Box 3211, San Francisco, California 94143, USA. Telephone: 415‐353‐7286; e‐mail: <email>andrew.ko@ucsf.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>9</month><year>2017</year></pub-date><volume>22</volume><issue>12</issue><issue-id pub-id-type="doi">10.1002/onco.v22.12</issue-id><fpage>1427</fpage><lpage>e129</lpage><history><date date-type="received"><day>29</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>07</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">© AlphaMed Press; the data published online to support this summary is the property of the authors</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="onco12239.pdf"></self-uri><abstract><title><offsets xml_i="7422" xml_f="7430" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="onco12239-sec-1001"><title><offsets xml_i="7474" xml_f="7490" txt_i="20" txt_f="36">Lessons Learned.</offsets></title><p><offsets xml_i="7501" xml_f="7502" txt_i="37" txt_f="38">
</offsets><list list-type="bullet" id="onco12239-list-0002"><list-item id="onco12239-li-0005"><p><offsets xml_i="7589" xml_f="7826" txt_i="38" txt_f="275">The addition of the heat shock protein 27 (Hsp27)‐targeting antisense oligonucleotide, apatorsen, to a standard first‐line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer.</offsets></p></list-item><list-item id="onco12239-li-0006"><p><offsets xml_i="7879" xml_f="8011" txt_i="276" txt_f="408">Findings from this trial hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.</offsets></p></list-item></list></p></sec><sec id="onco12239-sec-1202"><title><offsets xml_i="8080" xml_f="8091" txt_i="411" txt_f="422">Background.</offsets></title><p><offsets xml_i="8102" xml_f="8358" txt_i="423" txt_f="679">This randomized, double‐blinded, phase II trial evaluated the efficacy of gemcitabine/nab‐paclitaxel plus either apatorsen, an antisense oligonucleotide targeting heat shock protein 27 (Hsp27) mRNA, or placebo in patients with metastatic pancreatic cancer.</offsets></p></sec><sec id="onco12239-sec-1102"><title><offsets xml_i="8404" xml_f="8412" txt_i="681" txt_f="689">Methods.</offsets></title><p><offsets xml_i="8423" xml_f="8786" txt_i="690" txt_f="1053">Patients were randomized 1:1 to Arm A (gemcitabine/nab‐paclitaxel plus apatorsen) or Arm B (gemcitabine/nab‐paclitaxel plus placebo). Treatment was administered in 28‐day cycles, with restaging every 2 cycles, until progression or intolerable toxicity. Serum Hsp27 levels were analyzed at baseline and on treatment. The primary endpoint was overall survival (OS).</offsets></p></sec><sec id="onco12239-sec-1101"><title><offsets xml_i="8832" xml_f="8840" txt_i="1055" txt_f="1063">Results.</offsets></title><p><offsets xml_i="8851" xml_f="9347" txt_i="1064" txt_f="1560">One hundred thirty‐two patients were enrolled, 66 per arm. Cytopenias and fatigue were the most frequent grade 3/4 treatment‐related adverse events for both arms. Median progression‐free survival (PFS) and OS were 2.7 and 5.3 months, respectively, for arm A, and 3.8 and 6.9 months, respectively, for arm B. Objective response rate was 18% for both arms. Patients with high serum level of Hsp27 represented a poor‐prognosis subgroup who may have derived modest benefit from addition of apatorsen.</offsets></p></sec><sec id="onco12239-sec-1111"><title><offsets xml_i="9393" xml_f="9404" txt_i="1562" txt_f="1573">Conclusion.</offsets></title><p><offsets xml_i="9415" xml_f="9721" txt_i="1574" txt_f="1880">Addition of apatorsen to chemotherapy does not improve outcomes in unselected patients with metastatic pancreatic cancer in the first‐line setting, although a trend toward prolonged PFS and OS in patients with high baseline serum Hsp27 suggests this therapy may warrant further evaluation in this subgroup.</offsets></p></sec></abstract><trans-abstract xml:lang="zh" abstract-type="main"><p xml:lang="zh"><bold>经验总结</bold></p><p xml:lang="zh">• 在非经选转移性胰腺癌患者的标准一线化疗方案中添加靶向热休克蛋白27 (Hsp27) 的反义寡核苷酸apatorsen不会延长生存期。</p><p xml:lang="zh">•本试验的结果提示血清Hsp27可能具有预后和预测价值, 但需进行进一步研究。</p><p xml:lang="zh"><bold>摘要</bold></p><p xml:lang="zh"><bold><italic>背景</italic>.</bold>本项随机、双盲、II期试验评价了吉西他滨/白蛋白结合型紫杉醇联合apatorsen[靶向热休克蛋白27 (Hsp27) mRNA的反义寡核苷酸]或安慰剂治疗转移性胰腺癌患者的效果。</p><p xml:lang="zh"><bold><italic>方法</italic>.</bold>患者按1:1的比例被随机分配进入A组（吉西他滨/白蛋白结合型紫杉醇联合apatorsen）或B组（吉西他滨/白蛋白结合型紫杉醇联合安慰剂）。治疗周期为28天, 每2个周期对疾病进行一次重新分期, 直至出现疾病进展或不可耐受的毒性。在基线期和治疗期间分析了血清Hsp27水平。主要终点为总生存期（OS）。</p><p xml:lang="zh"><bold><italic>结果</italic>.</bold>共入组了132例患者, 每组66例。血细胞减少和疲乏是两组中最常见的3/4级治疗相关不良事件。A组的中位无进展生存期（PFS）和OS分别为2.7和5.3个月；B组分别为3.8和6.9个月。两组的客观缓解率均为18%。Hsp27血清水平较高的患者代表可能已经从添加apatorsen中适度获益的预后不佳亚组。</p><p xml:lang="zh"><bold><italic>结论</italic>.</bold>在非经选转移性胰腺癌患者的一线化疗中添加apatorsen不会改善治疗结局, 但基线期血清Hsp27水平较高患者的PFS和OS延长的趋势表明可能需在该亚组中对这一疗法进行进一步研究。</p></trans-abstract><counts><page-count count="15"></page-count></counts></article-meta></front><body><sec sec-type="discussion" id="onco12239-sec-0005"><title><offsets xml_i="10874" xml_f="10884" txt_i="1889" txt_f="1899">Discussion</offsets></title><p><offsets xml_i="10895" xml_f="11141" txt_i="1900" txt_f="2146">Heat shock protein 27 (Hsp27) is a protein chaperone whose expression is induced by cytotoxic chemotherapy, as well as other cell stressors such as hyperthermia, oxidative stress, and radiation, resulting in cytoprotection against these insults [</offsets><xref rid="onco12239-bib-0001" ref-type="ref"><offsets xml_i="11187" xml_f="11188" txt_i="2146" txt_f="2147">1</offsets></xref><offsets xml_i="11195" xml_f="11199" txt_i="2147" txt_f="2151">], [</offsets><xref rid="onco12239-bib-0002" ref-type="ref"><offsets xml_i="11245" xml_f="11246" txt_i="2151" txt_f="2152">2</offsets></xref><offsets xml_i="11253" xml_f="11480" txt_i="2152" txt_f="2379">]. Various malignancies, including pancreatic adenocarcinoma, overexpress Hsp27 [3]; furthermore, preclinical studies show that Hsp27 expression may play a role in the resistance of pancreatic cancer cell lines to gemcitabine [</offsets><xref rid="onco12239-bib-0004" ref-type="ref"><offsets xml_i="11526" xml_f="11527" txt_i="2379" txt_f="2380">4</offsets></xref><offsets xml_i="11534" xml_f="11538" txt_i="2380" txt_f="2384">], [</offsets><xref rid="onco12239-bib-0005" ref-type="ref"><offsets xml_i="11584" xml_f="11585" txt_i="2384" txt_f="2385">5</offsets></xref><offsets xml_i="11592" xml_f="11596" txt_i="2385" txt_f="2389">], [</offsets><xref rid="onco12239-bib-0006" ref-type="ref"><offsets xml_i="11642" xml_f="11643" txt_i="2389" txt_f="2390">6</offsets></xref><offsets xml_i="11650" xml_f="11891" txt_i="2390" txt_f="2631">]. Thus, inhibiting Hsp27 activity represents a viable therapeutic strategy in this disease. Apatorsen, an antisense oligonucleotide designed to bind to Hsp27 mRNA and block its translation into functional protein, offers one such approach [</offsets><xref rid="onco12239-bib-0007" ref-type="ref"><offsets xml_i="11937" xml_f="11938" txt_i="2631" txt_f="2632">7</offsets></xref><offsets xml_i="11945" xml_f="11947" txt_i="2632" txt_f="2634">].</offsets></p><p><offsets xml_i="11954" xml_f="12374" txt_i="2635" txt_f="3055">On these bases, we performed a randomized phase II trial to compare the safety and efficacy of gemcitabine and nab‐paclitaxel in combination with either apatorsen or placebo in the first‐line setting for patients with metastatic pancreatic cancer. The planned sample size of 130 provided 80% power to detect a difference in median survival of 8.5 versus 13.4 months (hazard ratio [HR] for death, 0.634; 1‐sided a = 0.1).</offsets></p><table-wrap id="onco12239-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label><offsets xml_i="12475" xml_f="12483" txt_i="3056" txt_f="3064">Table 1.</offsets></label><caption><title><offsets xml_i="12507" xml_f="12567" txt_i="3064" txt_f="3124">Median PFS and OS stratified by heat shock protein 27 levels</offsets></title></caption><graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0001"><alt-text><offsets xml_i="12686" xml_f="12691" txt_i="3125" txt_f="3130">image</offsets></alt-text><permissions><copyright-holder><offsets xml_i="12733" xml_f="12760" txt_i="3130" txt_f="3153">John Wiley &amp; Sons, Ltd.</offsets></copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12239-note-0002"><p><offsets xml_i="12852" xml_f="12975" txt_i="3153" txt_f="3276">Abbreviations: CI, confidence interval; Hsp27, heat shock protein 27; OS, overall survival; PFS, progression‐free survival.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="13018" xml_f="13748" txt_i="3277" txt_f="4007">Although the incidence of toxicities did not differ significantly between the two treatment arms (most common treatment‐related toxicities of all grades on both arms included fatigue, cytopenias, and gastrointestinal symptoms), the addition of apatorsen to chemotherapy did not produce any improvement in clinical outcomes in the intent‐to‐treat population. The objective response rate (ORR) was identical (18%) on both treatment arms, whereas patients on the apatorsen arm fared numerically worse in terms of both progression‐free survival (PFS) and overall survival (OS) when compared with patients on the placebo arm, although these differences were not statistically significant (median PFS, 2.7 vs. 3.8 months, respectively [</offsets><italic><offsets xml_i="13756" xml_f="13757" txt_i="4007" txt_f="4008">p</offsets></italic><offsets xml_i="13766" xml_f="13828" txt_i="4008" txt_f="4070"> = .92; HR 1.0]; median OS, 5.3 vs. 6.9 months, respectively [</offsets><italic><offsets xml_i="13836" xml_f="13837" txt_i="4070" txt_f="4071">p</offsets></italic><offsets xml_i="13846" xml_f="14104" txt_i="4071" txt_f="4329"> = .62; HR 1.1]). Notably, the survival outcomes for patients on both arms of this study were considerably inferior to those observed on the gemcitabine/nab‐paclitaxel arm from the phase III Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study [</offsets><xref rid="onco12239-bib-0008" ref-type="ref"><offsets xml_i="14150" xml_f="14151" txt_i="4329" txt_f="4330">8</offsets></xref><offsets xml_i="14158" xml_f="14181" txt_i="4330" txt_f="4353">], for unclear reasons.</offsets></p><p><offsets xml_i="14188" xml_f="14713" txt_i="4354" txt_f="4879">The only subgroup for whom a potential benefit of apatorsen could be identified was those patients with high serum levels of Hsp27, a marker associated with a very poor prognosis overall (median PFS for patients with high baseline serum Hsp27 levels, 3.3 vs. 0.9 months for apatorsen vs. placebo, respectively [HR 0.38], median OS 3.3 vs. 1.0 months [HR 0.59]). However, the number of subjects who fit into this category was too small, representing only 14% of the entire study population, to draw any definitive conclusions.</offsets></p><p><offsets xml_i="14720" xml_f="15191" txt_i="4880" txt_f="5351">In summary, the addition of apatorsen to a standard combination chemotherapy regimen in the first‐line setting did not result in improvement in survival or other clinically relevant endpoints in patients with metastatic pancreatic cancer. Although further studies of this agent in unselected patients do not appear to be indicated, the findings from this trial do hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.</offsets></p></sec><sec id="onco12239-sec-0006"><title><offsets xml_i="15237" xml_f="15254" txt_i="5353" txt_f="5370">Trial Information</offsets></title><p><offsets xml_i="15265" xml_f="15266" txt_i="5371" txt_f="5372">
</offsets><def-list id="onco12239-lp-0001"><def-item><term id="onco12239-li-0007"><offsets xml_i="15338" xml_f="15345" txt_i="5372" txt_f="5379">Disease</offsets></term><def id="onco12239-li-0008"><p><offsets xml_i="15383" xml_f="15419" txt_i="5379" txt_f="5415">Metastatic pancreatic adenocarcinoma</offsets></p></def></def-item><def-item><term id="onco12239-li-0009"><offsets xml_i="15479" xml_f="15505" txt_i="5416" txt_f="5442">Stage of Disease/Treatment</offsets></term><def id="onco12239-li-0010"><p><offsets xml_i="15543" xml_f="15562" txt_i="5442" txt_f="5461">Metastatic/advanced</offsets></p></def></def-item><def-item><term id="onco12239-li-0011"><offsets xml_i="15622" xml_f="15635" txt_i="5462" txt_f="5475">Prior Therapy</offsets></term><def id="onco12239-li-0012"><p><offsets xml_i="15673" xml_f="15677" txt_i="5475" txt_f="5479">None</offsets></p></def></def-item><def-item><term id="onco12239-li-0013"><offsets xml_i="15737" xml_f="15754" txt_i="5480" txt_f="5497">Type of Study – 1</offsets></term><def id="onco12239-li-0014"><p><offsets xml_i="15792" xml_f="15800" txt_i="5497" txt_f="5505">Phase II</offsets></p></def></def-item><def-item><term id="onco12239-li-0015"><offsets xml_i="15860" xml_f="15877" txt_i="5506" txt_f="5523">Type of Study – 2</offsets></term><def id="onco12239-li-0016"><p><offsets xml_i="15915" xml_f="15925" txt_i="5523" txt_f="5533">Randomized</offsets></p></def></def-item><def-item><term id="onco12239-li-0019"><offsets xml_i="15985" xml_f="15988" txt_i="5534" txt_f="5537">PFS</offsets></term><def id="onco12239-li-0020"><p><italic><offsets xml_i="16034" xml_f="16035" txt_i="5537" txt_f="5538">p</offsets></italic><offsets xml_i="16044" xml_f="16060" txt_i="5538" txt_f="5554"> = 0.92, HR: 1.0</offsets></p></def></def-item><def-item><term id="onco12239-li-0021"><offsets xml_i="16120" xml_f="16122" txt_i="5555" txt_f="5557">OS</offsets></term><def id="onco12239-li-0022"><p><italic><offsets xml_i="16168" xml_f="16169" txt_i="5557" txt_f="5558">p</offsets></italic><offsets xml_i="16178" xml_f="16194" txt_i="5558" txt_f="5574"> = 0.62, HR: 1.1</offsets></p></def></def-item><def-item><term id="onco12239-li-0025"><offsets xml_i="16254" xml_f="16270" txt_i="5575" txt_f="5591">Primary Endpoint</offsets></term><def id="onco12239-li-0026"><p><offsets xml_i="16308" xml_f="16324" txt_i="5591" txt_f="5607">Overall survival</offsets></p></def></def-item><def-item><term id="onco12239-li-0027"><offsets xml_i="16384" xml_f="16402" txt_i="5608" txt_f="5626">Secondary Endpoint</offsets></term><def id="onco12239-li-0028"><p><offsets xml_i="16440" xml_f="16465" txt_i="5626" txt_f="5651">Progression‐free survival</offsets></p></def></def-item><def-item><term id="onco12239-li-0029"><offsets xml_i="16525" xml_f="16543" txt_i="5652" txt_f="5670">Secondary Endpoint</offsets></term><def id="onco12239-li-0030"><p><offsets xml_i="16581" xml_f="16589" txt_i="5670" txt_f="5678">Toxicity</offsets></p></def></def-item><def-item><term id="onco12239-li-0031"><offsets xml_i="16649" xml_f="16672" txt_i="5679" txt_f="5702">Investigator's Analysis</offsets></term><def id="onco12239-li-0032"><p><offsets xml_i="16710" xml_f="16779" txt_i="5702" txt_f="5771">Feasible, possibly effective in patients with high Hsp27 serum levels</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0007"><title><offsets xml_i="16857" xml_f="16894" txt_i="5774" txt_f="5811">Drug Information for Phase II Control</offsets></title><p><offsets xml_i="16905" xml_f="16906" txt_i="5812" txt_f="5813">
</offsets><def-list id="onco12239-lp-0002"><def-item><term id="onco12239-li-0033"><offsets xml_i="16978" xml_f="16984" txt_i="5813" txt_f="5819">Drug 1</offsets></term><def id="onco12239-li-0034"><p><offsets xml_i="17022" xml_f="17023" txt_i="5819" txt_f="5820"> </offsets></p></def></def-item><def-item><term id="onco12239-li-0035"><offsets xml_i="17083" xml_f="17103" txt_i="5821" txt_f="5841">Generic/Working name</offsets></term><def id="onco12239-li-0036"><p><offsets xml_i="17141" xml_f="17155" txt_i="5841" txt_f="5855">Nab‐paclitaxel</offsets></p></def></def-item><def-item><term id="onco12239-li-0037"><offsets xml_i="17215" xml_f="17225" txt_i="5856" txt_f="5866">Trade name</offsets></term><def id="onco12239-li-0038"><p><offsets xml_i="17263" xml_f="17271" txt_i="5866" txt_f="5874">Abraxane</offsets></p></def></def-item><def-item><term id="onco12239-li-0039"><offsets xml_i="17331" xml_f="17343" txt_i="5875" txt_f="5887">Company name</offsets></term><def id="onco12239-li-0040"><p><offsets xml_i="17381" xml_f="17388" txt_i="5887" txt_f="5894">Celgene</offsets></p></def></def-item><def-item><term id="onco12239-li-0041"><offsets xml_i="17448" xml_f="17457" txt_i="5895" txt_f="5904">Drug type</offsets></term><def id="onco12239-li-0042"><p><offsets xml_i="17495" xml_f="17500" txt_i="5904" txt_f="5909">Other</offsets></p></def></def-item><def-item><term id="onco12239-li-0043"><offsets xml_i="17560" xml_f="17570" txt_i="5910" txt_f="5920">Drug class</offsets></term><def id="onco12239-li-0044"><p><offsets xml_i="17608" xml_f="17635" txt_i="5920" txt_f="5947">Microtubule‐targeting agent</offsets></p></def></def-item><def-item><term id="onco12239-li-0045"><offsets xml_i="17695" xml_f="17699" txt_i="5948" txt_f="5952">Dose</offsets></term><def id="onco12239-li-0046"><p><offsets xml_i="17737" xml_f="17776" txt_i="5952" txt_f="5991">125 milligrams (mg) per square meter (m</offsets><sup><offsets xml_i="17781" xml_f="17782" txt_i="5991" txt_f="5992">2</offsets></sup><offsets xml_i="17788" xml_f="17789" txt_i="5992" txt_f="5993">)</offsets></p></def></def-item><def-item><term id="onco12239-li-0047"><offsets xml_i="17849" xml_f="17854" txt_i="5994" txt_f="5999">Route</offsets></term><def id="onco12239-li-0048"><p><offsets xml_i="17892" xml_f="17894" txt_i="5999" txt_f="6001">IV</offsets></p></def></def-item><def-item><term id="onco12239-li-0049"><offsets xml_i="17954" xml_f="17980" txt_i="6002" txt_f="6028">Schedule of administration</offsets></term><def id="onco12239-li-0050"><p><offsets xml_i="18018" xml_f="18132" txt_i="6028" txt_f="6142">Placebo days 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycle</offsets></p></def></def-item><def-item><term id="onco12239-li-0053"><offsets xml_i="18192" xml_f="18198" txt_i="6143" txt_f="6149">Drug 2</offsets></term><def id="onco12239-li-0054"><p><offsets xml_i="18236" xml_f="18237" txt_i="6149" txt_f="6150"> </offsets></p></def></def-item><def-item><term id="onco12239-li-0055"><offsets xml_i="18297" xml_f="18317" txt_i="6151" txt_f="6171">Generic/Working name</offsets></term><def id="onco12239-li-0056"><p><offsets xml_i="18355" xml_f="18366" txt_i="6171" txt_f="6182">Gemcitabine</offsets></p></def></def-item><def-item><term id="onco12239-li-0057"><offsets xml_i="18426" xml_f="18436" txt_i="6183" txt_f="6193">Trade name</offsets></term><def id="onco12239-li-0058"><p><offsets xml_i="18474" xml_f="18480" txt_i="6193" txt_f="6199">Gemzar</offsets></p></def></def-item><def-item><term id="onco12239-li-0059"><offsets xml_i="18540" xml_f="18552" txt_i="6200" txt_f="6212">Company name</offsets></term><def id="onco12239-li-0060"><p><offsets xml_i="18590" xml_f="18599" txt_i="6212" txt_f="6221">Eli Lilly</offsets></p></def></def-item><def-item><term id="onco12239-li-0061"><offsets xml_i="18659" xml_f="18668" txt_i="6222" txt_f="6231">Drug type</offsets></term><def id="onco12239-li-0062"><p><offsets xml_i="18706" xml_f="18711" txt_i="6231" txt_f="6236">Other</offsets></p></def></def-item><def-item><term id="onco12239-li-0063"><offsets xml_i="18771" xml_f="18781" txt_i="6237" txt_f="6247">Drug class</offsets></term><def id="onco12239-li-0064"><p><offsets xml_i="18819" xml_f="18833" txt_i="6247" txt_f="6261">Antimetabolite</offsets></p></def></def-item><def-item><term id="onco12239-li-0065"><offsets xml_i="18893" xml_f="18897" txt_i="6262" txt_f="6266">Dose</offsets></term><def id="onco12239-li-0066"><p><offsets xml_i="18935" xml_f="18945" txt_i="6266" txt_f="6276">1,000 mg/m</offsets><sup><offsets xml_i="18950" xml_f="18951" txt_i="6276" txt_f="6277">2</offsets></sup></p></def></def-item><def-item><term id="onco12239-li-0067"><offsets xml_i="19017" xml_f="19022" txt_i="6278" txt_f="6283">Route</offsets></term><def id="onco12239-li-0068"><p><offsets xml_i="19060" xml_f="19062" txt_i="6283" txt_f="6285">IV</offsets></p></def></def-item><def-item><term id="onco12239-li-0069"><offsets xml_i="19122" xml_f="19148" txt_i="6286" txt_f="6312">Schedule of administration</offsets></term><def id="onco12239-li-0070"><p><offsets xml_i="19186" xml_f="19300" txt_i="6312" txt_f="6426">Placebo days 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycle</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0008"><title><offsets xml_i="19378" xml_f="19420" txt_i="6429" txt_f="6471">Drug Information for Phase II Experimental</offsets></title><p><offsets xml_i="19431" xml_f="19432" txt_i="6472" txt_f="6473">
</offsets><def-list id="onco12239-lp-0003"><def-item><term id="onco12239-li-0073"><offsets xml_i="19504" xml_f="19510" txt_i="6473" txt_f="6479">Drug 1</offsets></term><def id="onco12239-li-0074"><p><offsets xml_i="19548" xml_f="19549" txt_i="6479" txt_f="6480"> </offsets></p></def></def-item><def-item><term id="onco12239-li-0075"><offsets xml_i="19609" xml_f="19629" txt_i="6481" txt_f="6501">Generic/Working name</offsets></term><def id="onco12239-li-0076"><p><offsets xml_i="19667" xml_f="19676" txt_i="6501" txt_f="6510">Apatorsen</offsets></p></def></def-item><def-item><term id="onco12239-li-0077"><offsets xml_i="19736" xml_f="19746" txt_i="6511" txt_f="6521">Trade name</offsets></term><def id="onco12239-li-0078"><p><offsets xml_i="19784" xml_f="19798" txt_i="6521" txt_f="6535">Not applicable</offsets></p></def></def-item><def-item><term id="onco12239-li-0079"><offsets xml_i="19858" xml_f="19870" txt_i="6536" txt_f="6548">Company name</offsets></term><def id="onco12239-li-0080"><p><offsets xml_i="19908" xml_f="19917" txt_i="6548" txt_f="6557">OncoGenex</offsets></p></def></def-item><def-item><term id="onco12239-li-0081"><offsets xml_i="19977" xml_f="19986" txt_i="6558" txt_f="6567">Drug type</offsets></term><def id="onco12239-li-0082"><p><offsets xml_i="20024" xml_f="20029" txt_i="6567" txt_f="6572">Other</offsets></p></def></def-item><def-item><term id="onco12239-li-0083"><offsets xml_i="20089" xml_f="20099" txt_i="6573" txt_f="6583">Drug class</offsets></term><def id="onco12239-li-0084"><p><offsets xml_i="20137" xml_f="20162" txt_i="6583" txt_f="6608">Antisense oligonucleotide</offsets></p></def></def-item><def-item><term id="onco12239-li-0085"><offsets xml_i="20222" xml_f="20226" txt_i="6609" txt_f="6613">Dose</offsets></term><def id="onco12239-li-0086"><p><offsets xml_i="20264" xml_f="20284" txt_i="6613" txt_f="6633">600 mg per flat dose</offsets></p></def></def-item><def-item><term id="onco12239-li-0087"><offsets xml_i="20344" xml_f="20349" txt_i="6634" txt_f="6639">Route</offsets></term><def id="onco12239-li-0088"><p><offsets xml_i="20387" xml_f="20389" txt_i="6639" txt_f="6641">IV</offsets></p></def></def-item><def-item><term id="onco12239-li-0089"><offsets xml_i="20449" xml_f="20475" txt_i="6642" txt_f="6668">Schedule of administration</offsets></term><def id="onco12239-li-0090"><p><offsets xml_i="20513" xml_f="20629" txt_i="6668" txt_f="6784">Apatorsen days 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycle</offsets></p></def></def-item><def-item><term id="onco12239-li-0093"><offsets xml_i="20689" xml_f="20695" txt_i="6785" txt_f="6791">Drug 2</offsets></term><def id="onco12239-li-0094"><p><offsets xml_i="20733" xml_f="20734" txt_i="6791" txt_f="6792"> </offsets></p></def></def-item><def-item><term id="onco12239-li-0095"><offsets xml_i="20794" xml_f="20814" txt_i="6793" txt_f="6813">Generic/Working name</offsets></term><def id="onco12239-li-0096"><p><offsets xml_i="20852" xml_f="20866" txt_i="6813" txt_f="6827">Nab‐paclitaxel</offsets></p></def></def-item><def-item><term id="onco12239-li-0097"><offsets xml_i="20926" xml_f="20936" txt_i="6828" txt_f="6838">Trade name</offsets></term><def id="onco12239-li-0098"><p><offsets xml_i="20974" xml_f="20982" txt_i="6838" txt_f="6846">Abraxane</offsets></p></def></def-item><def-item><term id="onco12239-li-0099"><offsets xml_i="21042" xml_f="21054" txt_i="6847" txt_f="6859">Company name</offsets></term><def id="onco12239-li-0100"><p><offsets xml_i="21092" xml_f="21099" txt_i="6859" txt_f="6866">Celgene</offsets></p></def></def-item><def-item><term id="onco12239-li-0101"><offsets xml_i="21159" xml_f="21168" txt_i="6867" txt_f="6876">Drug type</offsets></term><def id="onco12239-li-0102"><p><offsets xml_i="21206" xml_f="21211" txt_i="6876" txt_f="6881">Other</offsets></p></def></def-item><def-item><term id="onco12239-li-0103"><offsets xml_i="21271" xml_f="21281" txt_i="6882" txt_f="6892">Drug class</offsets></term><def id="onco12239-li-0104"><p><offsets xml_i="21319" xml_f="21346" txt_i="6892" txt_f="6919">Microtubule‐targeting agent</offsets></p></def></def-item><def-item><term id="onco12239-li-0105"><offsets xml_i="21406" xml_f="21410" txt_i="6920" txt_f="6924">Dose</offsets></term><def id="onco12239-li-0106"><p><offsets xml_i="21448" xml_f="21456" txt_i="6924" txt_f="6932">125 mg/m</offsets><sup><offsets xml_i="21461" xml_f="21462" txt_i="6932" txt_f="6933">2</offsets></sup></p></def></def-item><def-item><term id="onco12239-li-0107"><offsets xml_i="21528" xml_f="21554" txt_i="6934" txt_f="6960">Schedule of administration</offsets></term><def id="onco12239-li-0108"><p><offsets xml_i="21592" xml_f="21713" txt_i="6960" txt_f="7081">Apatorsen days 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycle pfof</offsets></p></def></def-item><def-item><term id="onco12239-li-0111"><offsets xml_i="21773" xml_f="21779" txt_i="7082" txt_f="7088">Drug 3</offsets></term><def id="onco12239-li-0112"><p><offsets xml_i="21817" xml_f="21818" txt_i="7088" txt_f="7089"> </offsets></p></def></def-item><def-item><term id="onco12239-li-0113"><offsets xml_i="21878" xml_f="21898" txt_i="7090" txt_f="7110">Generic/Working name</offsets></term><def id="onco12239-li-0114"><p><offsets xml_i="21936" xml_f="21947" txt_i="7110" txt_f="7121">Gemcitabine</offsets></p></def></def-item><def-item><term id="onco12239-li-0115"><offsets xml_i="22007" xml_f="22017" txt_i="7122" txt_f="7132">Trade name</offsets></term><def id="onco12239-li-0116"><p><offsets xml_i="22055" xml_f="22061" txt_i="7132" txt_f="7138">Gemzar</offsets></p></def></def-item><def-item><term id="onco12239-li-0117"><offsets xml_i="22121" xml_f="22133" txt_i="7139" txt_f="7151">Company name</offsets></term><def id="onco12239-li-0118"><p><offsets xml_i="22171" xml_f="22180" txt_i="7151" txt_f="7160">Eli Lilly</offsets></p></def></def-item><def-item><term id="onco12239-li-0119"><offsets xml_i="22240" xml_f="22249" txt_i="7161" txt_f="7170">Drug type</offsets></term><def id="onco12239-li-0120"><p><offsets xml_i="22287" xml_f="22292" txt_i="7170" txt_f="7175">Other</offsets></p></def></def-item><def-item><term id="onco12239-li-0121"><offsets xml_i="22352" xml_f="22362" txt_i="7176" txt_f="7186">Drug class</offsets></term><def id="onco12239-li-0122"><p><offsets xml_i="22400" xml_f="22414" txt_i="7186" txt_f="7200">Antimetabolite</offsets></p></def></def-item><def-item><term id="onco12239-li-0123"><offsets xml_i="22474" xml_f="22478" txt_i="7201" txt_f="7205">Dose</offsets></term><def id="onco12239-li-0124"><p><offsets xml_i="22516" xml_f="22526" txt_i="7205" txt_f="7215">1,000 mg/m</offsets><sup><offsets xml_i="22531" xml_f="22532" txt_i="7215" txt_f="7216">2</offsets></sup></p></def></def-item><def-item><term id="onco12239-li-0125"><offsets xml_i="22598" xml_f="22603" txt_i="7217" txt_f="7222">Route</offsets></term><def id="onco12239-li-0126"><p><offsets xml_i="22641" xml_f="22643" txt_i="7222" txt_f="7224">IV</offsets></p></def></def-item><def-item><term id="onco12239-li-0127"><offsets xml_i="22703" xml_f="22729" txt_i="7225" txt_f="7251">Schedule of administration</offsets></term><def id="onco12239-li-0128"><p><offsets xml_i="22767" xml_f="22878" txt_i="7251" txt_f="7362">Apatorsen 1, 8, 15, and 22 of a 28‐day cycle Nab‐paclitaxel and gemcitabine days 1, 8, and 15 of a 28‐day cycle</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0009"><title><offsets xml_i="22956" xml_f="23000" txt_i="7365" txt_f="7409">Patient Characteristics for Phase II Control</offsets></title><p><offsets xml_i="23011" xml_f="23012" txt_i="7410" txt_f="7411">
</offsets><def-list id="onco12239-lp-0004"><def-item><term id="onco12239-li-0131"><offsets xml_i="23084" xml_f="23108" txt_i="7411" txt_f="7435">Number of Patients, Male</offsets></term><def id="onco12239-li-0132"><p><offsets xml_i="23146" xml_f="23148" txt_i="7435" txt_f="7437">38</offsets></p></def></def-item><def-item><term id="onco12239-li-0133"><offsets xml_i="23208" xml_f="23234" txt_i="7438" txt_f="7464">Number of Patients, Female</offsets></term><def id="onco12239-li-0134"><p><offsets xml_i="23272" xml_f="23274" txt_i="7464" txt_f="7466">28</offsets></p></def></def-item><def-item><term id="onco12239-li-0135"><offsets xml_i="23334" xml_f="23339" txt_i="7467" txt_f="7472">Stage</offsets></term><def id="onco12239-li-0136"><p><offsets xml_i="23377" xml_f="23379" txt_i="7472" txt_f="7474">IV</offsets></p></def></def-item><def-item><term id="onco12239-li-0137"><offsets xml_i="23439" xml_f="23442" txt_i="7475" txt_f="7478">Age</offsets></term><def id="onco12239-li-0138"><p><offsets xml_i="23480" xml_f="23508" txt_i="7478" txt_f="7506">Median (range): 65.5 (47–83)</offsets></p></def></def-item><def-item><term id="onco12239-li-0139"><offsets xml_i="23568" xml_f="23602" txt_i="7507" txt_f="7541">Number of Prior Systemic Therapies</offsets></term><def id="onco12239-li-0140"><p><offsets xml_i="23640" xml_f="23660" txt_i="7541" txt_f="7561">Median (range): None</offsets></p></def></def-item><def-item><term id="onco12239-li-0141"><offsets xml_i="23720" xml_f="23743" txt_i="7562" txt_f="7585">Performance Status ECOG</offsets></term><def id="onco12239-li-0142"><p><offsets xml_i="23781" xml_f="23787" txt_i="7585" txt_f="7591">0 — 32</offsets></p><p><offsets xml_i="23794" xml_f="23800" txt_i="7592" txt_f="7598">1 — 32</offsets></p><p><offsets xml_i="23807" xml_f="23810" txt_i="7599" txt_f="7602">2 —</offsets></p><p><offsets xml_i="23817" xml_f="23820" txt_i="7603" txt_f="7606">3 —</offsets></p><p><offsets xml_i="23827" xml_f="23838" txt_i="7607" txt_f="7618">Unknown — 2</offsets></p></def></def-item><def-item><term id="onco12239-li-0151"><offsets xml_i="23898" xml_f="23933" txt_i="7619" txt_f="7654">Cancer Types or Histologic Subtypes</offsets></term><def id="onco12239-li-0152"><p><offsets xml_i="23971" xml_f="23996" txt_i="7654" txt_f="7679">CA19‐9 levels ≤90 U/mL 11</offsets></p><p><offsets xml_i="24003" xml_f="24031" txt_i="7680" txt_f="7705">CA19‐9 levels &gt;90 U/mL 54</offsets></p><p><offsets xml_i="24038" xml_f="24061" txt_i="7706" txt_f="7729">CA19‐9 levels Unknown 1</offsets></p><p><offsets xml_i="24068" xml_f="24092" txt_i="7730" txt_f="7754">Hsp27 expression high 11</offsets></p><p><offsets xml_i="24099" xml_f="24122" txt_i="7755" txt_f="7778">Hsp27 expression low 47</offsets></p><p><offsets xml_i="24129" xml_f="24155" txt_i="7779" txt_f="7805">Hsp27 expression Unknown 8</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0010"><title><offsets xml_i="24233" xml_f="24282" txt_i="7808" txt_f="7857">Patient Characteristics for Phase II Experimental</offsets></title><p><offsets xml_i="24293" xml_f="24294" txt_i="7858" txt_f="7859">
</offsets><def-list id="onco12239-lp-0005"><def-item><term id="onco12239-li-0163"><offsets xml_i="24366" xml_f="24390" txt_i="7859" txt_f="7883">Number of Patients, Male</offsets></term><def id="onco12239-li-0164"><p><offsets xml_i="24428" xml_f="24430" txt_i="7883" txt_f="7885">37</offsets></p></def></def-item><def-item><term id="onco12239-li-0165"><offsets xml_i="24490" xml_f="24516" txt_i="7886" txt_f="7912">Number of Patients, Female</offsets></term><def id="onco12239-li-0166"><p><offsets xml_i="24554" xml_f="24556" txt_i="7912" txt_f="7914">29</offsets></p></def></def-item><def-item><term id="onco12239-li-0167"><offsets xml_i="24616" xml_f="24621" txt_i="7915" txt_f="7920">Stage</offsets></term><def id="onco12239-li-0168"><p><offsets xml_i="24659" xml_f="24661" txt_i="7920" txt_f="7922">IV</offsets></p></def></def-item><def-item><term id="onco12239-li-0169"><offsets xml_i="24721" xml_f="24724" txt_i="7923" txt_f="7926">Age</offsets></term><def id="onco12239-li-0170"><p><offsets xml_i="24762" xml_f="24790" txt_i="7926" txt_f="7954">Median (range): 66.5 (39–82)</offsets></p></def></def-item><def-item><term id="onco12239-li-0171"><offsets xml_i="24850" xml_f="24884" txt_i="7955" txt_f="7989">Number of Prior Systemic Therapies</offsets></term><def id="onco12239-li-0172"><p><offsets xml_i="24922" xml_f="24942" txt_i="7989" txt_f="8009">Median (range): None</offsets></p></def></def-item><def-item><term id="onco12239-li-0173"><offsets xml_i="25002" xml_f="25026" txt_i="8010" txt_f="8034">Performance Status: ECOG</offsets></term><def id="onco12239-li-0174"><p><offsets xml_i="25064" xml_f="25070" txt_i="8034" txt_f="8040">0 — 30</offsets></p><p><offsets xml_i="25077" xml_f="25083" txt_i="8041" txt_f="8047">1 — 36</offsets></p><p><offsets xml_i="25090" xml_f="25093" txt_i="8048" txt_f="8051">2 —</offsets></p><p><offsets xml_i="25100" xml_f="25103" txt_i="8052" txt_f="8055">3 —</offsets></p><p><offsets xml_i="25110" xml_f="25119" txt_i="8056" txt_f="8065">Unknown —</offsets></p></def></def-item><def-item><term id="onco12239-li-0183"><offsets xml_i="25179" xml_f="25214" txt_i="8066" txt_f="8101">Cancer Types or Histologic Subtypes</offsets></term><def id="onco12239-li-0184"><p><offsets xml_i="25252" xml_f="25277" txt_i="8101" txt_f="8126">CA19‐9 levels ≤90 U/mL 18</offsets></p><p><offsets xml_i="25284" xml_f="25312" txt_i="8127" txt_f="8152">CA19‐9 levels &gt;90 U/mL 47</offsets></p><p><offsets xml_i="25319" xml_f="25342" txt_i="8153" txt_f="8176">CA19‐9 levels unknown 1</offsets></p><p><offsets xml_i="25349" xml_f="25372" txt_i="8177" txt_f="8200">Hsp27 expression high 7</offsets></p><p><offsets xml_i="25379" xml_f="25402" txt_i="8201" txt_f="8224">Hsp27 expression low 55</offsets></p><p><offsets xml_i="25409" xml_f="25435" txt_i="8225" txt_f="8251">Hsp27 expression unknown 4</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0011"><title><offsets xml_i="25513" xml_f="25559" txt_i="8254" txt_f="8300">Primary Assessment Method for Phase II Control</offsets></title><p><offsets xml_i="25570" xml_f="25571" txt_i="8301" txt_f="8302">
</offsets><def-list id="onco12239-lp-0006"><def-item><term id="onco12239-li-0195"><offsets xml_i="25643" xml_f="25697" txt_i="8302" txt_f="8356">Assessment: Total Patient Population: Overall Survival</offsets></term><def id="onco12239-li-0196"><p><offsets xml_i="25735" xml_f="25736" txt_i="8356" txt_f="8357"> </offsets></p></def></def-item><def-item><term id="onco12239-li-0197"><offsets xml_i="25796" xml_f="25823" txt_i="8358" txt_f="8385">Number of patients screened</offsets></term><def id="onco12239-li-0198"><p><offsets xml_i="25861" xml_f="25863" txt_i="8385" txt_f="8387">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0199"><offsets xml_i="25923" xml_f="25950" txt_i="8388" txt_f="8415">Number of patients enrolled</offsets></term><def id="onco12239-li-0200"><p><offsets xml_i="25988" xml_f="25990" txt_i="8415" txt_f="8417">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0201"><offsets xml_i="26050" xml_f="26091" txt_i="8418" txt_f="8459">Number of patients evaluable for toxicity</offsets></term><def id="onco12239-li-0202"><p><offsets xml_i="26129" xml_f="26131" txt_i="8459" txt_f="8461">63</offsets></p></def></def-item><def-item><term id="onco12239-li-0203"><offsets xml_i="26191" xml_f="26232" txt_i="8462" txt_f="8503">Number of patients evaluated for efficacy</offsets></term><def id="onco12239-li-0204"><p><offsets xml_i="26270" xml_f="26272" txt_i="8503" txt_f="8505">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0205"><offsets xml_i="26332" xml_f="26349" txt_i="8506" txt_f="8523">Evaluation method</offsets></term><def id="onco12239-li-0206"><p><offsets xml_i="26387" xml_f="26397" txt_i="8523" txt_f="8533">RECIST 1.1</offsets></p></def></def-item><def-item><term id="onco12239-li-0207"><offsets xml_i="26457" xml_f="26479" txt_i="8534" txt_f="8556">Response assessment CR</offsets></term><def id="onco12239-li-0208"><p><italic><offsets xml_i="26525" xml_f="26526" txt_i="8556" txt_f="8557">n</offsets></italic><offsets xml_i="26535" xml_f="26544" txt_i="8557" txt_f="8566"> = 0 (0%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0209"><offsets xml_i="26604" xml_f="26626" txt_i="8567" txt_f="8589">Response assessment PR</offsets></term><def id="onco12239-li-0210"><p><italic><offsets xml_i="26672" xml_f="26673" txt_i="8589" txt_f="8590">n</offsets></italic><offsets xml_i="26682" xml_f="26693" txt_i="8590" txt_f="8601"> = 12 (18%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0211"><offsets xml_i="26753" xml_f="26775" txt_i="8602" txt_f="8624">Response assessment SD</offsets></term><def id="onco12239-li-0212"><p><italic><offsets xml_i="26821" xml_f="26822" txt_i="8624" txt_f="8625">n</offsets></italic><offsets xml_i="26831" xml_f="26842" txt_i="8625" txt_f="8636"> = 21 (32%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0213"><offsets xml_i="26902" xml_f="26924" txt_i="8637" txt_f="8659">Response assessment PD</offsets></term><def id="onco12239-li-0214"><p><italic><offsets xml_i="26970" xml_f="26971" txt_i="8659" txt_f="8660">n</offsets></italic><offsets xml_i="26980" xml_f="26991" txt_i="8660" txt_f="8671"> = 18 (28%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0215"><offsets xml_i="27051" xml_f="27076" txt_i="8672" txt_f="8697">Response assessment OTHER</offsets></term><def id="onco12239-li-0216"><p><italic><offsets xml_i="27122" xml_f="27123" txt_i="8697" txt_f="8698">n</offsets></italic><offsets xml_i="27132" xml_f="27143" txt_i="8698" txt_f="8709"> = 15 (22%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0217"><offsets xml_i="27203" xml_f="27236" txt_i="8710" txt_f="8743">(Median) duration assessments PFS</offsets></term><def id="onco12239-li-0218"><p><offsets xml_i="27274" xml_f="27284" txt_i="8743" txt_f="8753">3.8 months</offsets></p></def></def-item><def-item><term id="onco12239-li-0219"><offsets xml_i="27344" xml_f="27376" txt_i="8754" txt_f="8786">(Median) duration assessments OS</offsets></term><def id="onco12239-li-0220"><p><offsets xml_i="27414" xml_f="27424" txt_i="8786" txt_f="8796">6.9 months</offsets></p></def></def-item><def-item><term id="onco12239-li-8219"><offsets xml_i="27484" xml_f="27507" txt_i="8797" txt_f="8820">Kaplan‐Meier time units</offsets></term><def id="onco12239-li-7220"><p><offsets xml_i="27545" xml_f="27551" txt_i="8820" txt_f="8826">months</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-1012"><p><boxed-text position="anchor" content-type="graphic" orientation="portrait"><caption><p><offsets xml_i="27713" xml_f="27812" txt_i="8829" txt_f="8928">Waterfall plot demonstrating best objective response in response‐evaluable subjects on control arm.</offsets></p></caption><graphic xlink:href="onco12239-fig-0001.jpg" position="anchor" id="nlm-graphic-3" specific-use="sourcefile-name" orientation="portrait"><alt-text><offsets xml_i="27972" xml_f="27977" txt_i="8929" txt_f="8934">image</offsets></alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-1632"><p><offsets xml_i="28053" xml_f="28054" txt_i="8936" txt_f="8937">
</offsets><table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-7" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0002"><alt-text><offsets xml_i="28244" xml_f="28249" txt_i="8937" txt_f="8942">image</offsets></alt-text><permissions><copyright-holder><offsets xml_i="28291" xml_f="28318" txt_i="8942" txt_f="8965">John Wiley &amp; Sons, Ltd.</offsets></copyright-holder></permissions></graphic></table-wrap><offsets xml_i="28374" xml_f="28375" txt_i="8965" txt_f="8966">
</offsets></p></sec><sec id="onco12239-sec-7512"><p><boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12239-fig-0002.jpg" position="anchor" id="nlm-graphic-9" specific-use="sourcefile-name" orientation="portrait"><alt-text><offsets xml_i="28639" xml_f="28644" txt_i="8968" txt_f="8973">image</offsets></alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-0012"><title><offsets xml_i="28724" xml_f="28787" txt_i="8975" txt_f="9038">Assessment: Total Patient Population: Progression‐Free Survival</offsets></title><p><offsets xml_i="28798" xml_f="28799" txt_i="9039" txt_f="9040">
</offsets><def-list id="onco12239-lp-0007"><def-item><term id="onco12239-li-0221"><offsets xml_i="28871" xml_f="28898" txt_i="9040" txt_f="9067">Number of patients screened</offsets></term><def id="onco12239-li-0222"><p><offsets xml_i="28936" xml_f="28938" txt_i="9067" txt_f="9069">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0223"><offsets xml_i="28998" xml_f="29025" txt_i="9070" txt_f="9097">Number of patients enrolled</offsets></term><def id="onco12239-li-0224"><p><offsets xml_i="29063" xml_f="29065" txt_i="9097" txt_f="9099">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0225"><offsets xml_i="29125" xml_f="29166" txt_i="9100" txt_f="9141">Number of patients evaluable for toxicity</offsets></term><def id="onco12239-li-0226"><p><offsets xml_i="29204" xml_f="29206" txt_i="9141" txt_f="9143">63</offsets></p></def></def-item><def-item><term id="onco12239-li-0227"><offsets xml_i="29266" xml_f="29307" txt_i="9144" txt_f="9185">Number of patients evaluated for efficacy</offsets></term><def id="onco12239-li-0228"><p><offsets xml_i="29345" xml_f="29347" txt_i="9185" txt_f="9187">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0229"><offsets xml_i="29407" xml_f="29424" txt_i="9188" txt_f="9205">Evaluation method</offsets></term><def id="onco12239-li-0230"><p><offsets xml_i="29462" xml_f="29472" txt_i="9205" txt_f="9215">RECIST 1.1</offsets></p></def></def-item><def-item><term id="onco12239-li-0231"><offsets xml_i="29532" xml_f="29554" txt_i="9216" txt_f="9238">Response assessment CR</offsets></term><def id="onco12239-li-0232"><p><italic><offsets xml_i="29600" xml_f="29601" txt_i="9238" txt_f="9239">n</offsets></italic><offsets xml_i="29610" xml_f="29619" txt_i="9239" txt_f="9248"> = 0 (0%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0233"><offsets xml_i="29679" xml_f="29701" txt_i="9249" txt_f="9271">Response assessment PR</offsets></term><def id="onco12239-li-0234"><p><italic><offsets xml_i="29747" xml_f="29748" txt_i="9271" txt_f="9272">n</offsets></italic><offsets xml_i="29757" xml_f="29768" txt_i="9272" txt_f="9283"> = 12 (18%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0235"><offsets xml_i="29828" xml_f="29850" txt_i="9284" txt_f="9306">Response assessment SD</offsets></term><def id="onco12239-li-0236"><p><italic><offsets xml_i="29896" xml_f="29897" txt_i="9306" txt_f="9307">n</offsets></italic><offsets xml_i="29906" xml_f="29917" txt_i="9307" txt_f="9318"> = 21 (32%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0237"><offsets xml_i="29977" xml_f="29999" txt_i="9319" txt_f="9341">Response assessment PD</offsets></term><def id="onco12239-li-0238"><p><italic><offsets xml_i="30045" xml_f="30046" txt_i="9341" txt_f="9342">n</offsets></italic><offsets xml_i="30055" xml_f="30066" txt_i="9342" txt_f="9353"> = 18 (28%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0239"><offsets xml_i="30126" xml_f="30151" txt_i="9354" txt_f="9379">Response assessment OTHER</offsets></term><def id="onco12239-li-0240"><p><italic><offsets xml_i="30197" xml_f="30198" txt_i="9379" txt_f="9380">n</offsets></italic><offsets xml_i="30207" xml_f="30218" txt_i="9380" txt_f="9391"> = 15 (22%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0241"><offsets xml_i="30278" xml_f="30311" txt_i="9392" txt_f="9425">(Median) duration assessments PFS</offsets></term><def id="onco12239-li-0242"><p><offsets xml_i="30349" xml_f="30359" txt_i="9425" txt_f="9435">3.8 months</offsets></p></def></def-item><def-item><term id="onco12239-li-0243"><offsets xml_i="30419" xml_f="30451" txt_i="9436" txt_f="9468">(Median) duration assessments OS</offsets></term><def id="onco12239-li-0244"><p><offsets xml_i="30489" xml_f="30499" txt_i="9468" txt_f="9478">6.9 months</offsets></p></def></def-item><def-item><term id="onco12239-li-1243"><offsets xml_i="30559" xml_f="30582" txt_i="9479" txt_f="9502">Kaplan‐Meier time units</offsets></term><def id="onco12239-li-1244"><p><offsets xml_i="30620" xml_f="30626" txt_i="9502" txt_f="9508">months</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-1112"><p><offsets xml_i="30700" xml_f="30701" txt_i="9511" txt_f="9512">
</offsets><table-wrap id="nlm-table-wrap-2" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-13" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0003"><alt-text><offsets xml_i="30892" xml_f="30897" txt_i="9512" txt_f="9517">image</offsets></alt-text><permissions><copyright-holder><offsets xml_i="30939" xml_f="30966" txt_i="9517" txt_f="9540">John Wiley &amp; Sons, Ltd.</offsets></copyright-holder></permissions></graphic></table-wrap><offsets xml_i="31022" xml_f="31023" txt_i="9540" txt_f="9541">
</offsets></p></sec><sec id="onco12239-sec-2392"><p><offsets xml_i="31065" xml_f="31066" txt_i="9543" txt_f="9544">
</offsets><boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12239-fig-0003.jpg" position="anchor" id="nlm-graphic-15" specific-use="sourcefile-name" orientation="portrait"><alt-text><offsets xml_i="31289" xml_f="31294" txt_i="9544" txt_f="9549">image</offsets></alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-0013"><title><offsets xml_i="31374" xml_f="31425" txt_i="9551" txt_f="9602">Primary Assessment Method for Phase II Experimental</offsets></title><p><offsets xml_i="31436" xml_f="31437" txt_i="9603" txt_f="9604">
</offsets><def-list id="onco12239-lp-0008"><def-item><term id="onco12239-li-0245"><offsets xml_i="31509" xml_f="31563" txt_i="9604" txt_f="9658">Assessment: Total Patient Population: Overall Survival</offsets></term><def id="onco12239-li-0246"><p><offsets xml_i="31601" xml_f="31602" txt_i="9658" txt_f="9659"> </offsets></p></def></def-item><def-item><term id="onco12239-li-0247"><offsets xml_i="31662" xml_f="31689" txt_i="9660" txt_f="9687">Number of patients screened</offsets></term><def id="onco12239-li-0248"><p><offsets xml_i="31727" xml_f="31729" txt_i="9687" txt_f="9689">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0249"><offsets xml_i="31789" xml_f="31816" txt_i="9690" txt_f="9717">Number of patients enrolled</offsets></term><def id="onco12239-li-0250"><p><offsets xml_i="31854" xml_f="31856" txt_i="9717" txt_f="9719">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0251"><offsets xml_i="31916" xml_f="31957" txt_i="9720" txt_f="9761">Number of patients evaluable for toxicity</offsets></term><def id="onco12239-li-0252"><p><offsets xml_i="31995" xml_f="31997" txt_i="9761" txt_f="9763">64</offsets></p></def></def-item><def-item><term id="onco12239-li-0253"><offsets xml_i="32057" xml_f="32098" txt_i="9764" txt_f="9805">Number of patients evaluated for efficacy</offsets></term><def id="onco12239-li-0254"><p><offsets xml_i="32136" xml_f="32138" txt_i="9805" txt_f="9807">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0255"><offsets xml_i="32198" xml_f="32215" txt_i="9808" txt_f="9825">Evaluation method</offsets></term><def id="onco12239-li-0256"><p><offsets xml_i="32253" xml_f="32263" txt_i="9825" txt_f="9835">RECIST 1.1</offsets></p></def></def-item><def-item><term id="onco12239-li-0257"><offsets xml_i="32323" xml_f="32345" txt_i="9836" txt_f="9858">Response assessment CR</offsets></term><def id="onco12239-li-0258"><p><italic><offsets xml_i="32391" xml_f="32392" txt_i="9858" txt_f="9859">n</offsets></italic><offsets xml_i="32401" xml_f="32410" txt_i="9859" txt_f="9868"> = 0 (0%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0259"><offsets xml_i="32470" xml_f="32492" txt_i="9869" txt_f="9891">Response assessment PR</offsets></term><def id="onco12239-li-0260"><p><italic><offsets xml_i="32538" xml_f="32539" txt_i="9891" txt_f="9892">n</offsets></italic><offsets xml_i="32548" xml_f="32559" txt_i="9892" txt_f="9903"> = 12 (18%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0261"><offsets xml_i="32619" xml_f="32641" txt_i="9904" txt_f="9926">Response assessment SD</offsets></term><def id="onco12239-li-0262"><p><italic><offsets xml_i="32687" xml_f="32688" txt_i="9926" txt_f="9927">n</offsets></italic><offsets xml_i="32697" xml_f="32708" txt_i="9927" txt_f="9938"> = 16 (24%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0263"><offsets xml_i="32768" xml_f="32790" txt_i="9939" txt_f="9961">Response assessment PD</offsets></term><def id="onco12239-li-0264"><p><italic><offsets xml_i="32836" xml_f="32837" txt_i="9961" txt_f="9962">n</offsets></italic><offsets xml_i="32846" xml_f="32857" txt_i="9962" txt_f="9973"> = 21 (32%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0265"><offsets xml_i="32917" xml_f="32942" txt_i="9974" txt_f="9999">Response assessment OTHER</offsets></term><def id="onco12239-li-0266"><p><italic><offsets xml_i="32988" xml_f="32989" txt_i="9999" txt_f="10000">n</offsets></italic><offsets xml_i="32998" xml_f="33009" txt_i="10000" txt_f="10011"> = 17 (26%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0267"><offsets xml_i="33069" xml_f="33102" txt_i="10012" txt_f="10045">(Median) duration assessments PFS</offsets></term><def id="onco12239-li-0268"><p><offsets xml_i="33140" xml_f="33150" txt_i="10045" txt_f="10055">2.7 months</offsets></p></def></def-item><def-item><term id="onco12239-li-1269"><offsets xml_i="33210" xml_f="33242" txt_i="10056" txt_f="10088">(Median) duration assessments OS</offsets></term><def id="onco12239-li-1270"><p><offsets xml_i="33280" xml_f="33283" txt_i="10088" txt_f="10091">5.3</offsets></p></def></def-item><def-item><term id="onco12239-li-1219"><offsets xml_i="33343" xml_f="33366" txt_i="10092" txt_f="10115">Kaplan-Meier time units</offsets></term><def id="onco12239-li-1220"><p><offsets xml_i="33404" xml_f="33410" txt_i="10115" txt_f="10121">months</offsets></p></def></def-item></def-list><offsets xml_i="33442" xml_f="33443" txt_i="10122" txt_f="10123">
</offsets></p></sec><sec id="onco12239-sec-1395"><p><boxed-text position="anchor" content-type="graphic" orientation="portrait"><caption><p><offsets xml_i="33573" xml_f="33677" txt_i="10125" txt_f="10229">Waterfall plot demonstrating best objective response in response‐evaluable subjects on experimental arm.</offsets></p></caption><graphic xlink:href="onco12239-fig-0004.jpg" position="anchor" id="nlm-graphic-19" specific-use="sourcefile-name" orientation="portrait"><alt-text><offsets xml_i="33838" xml_f="33843" txt_i="10230" txt_f="10235">image</offsets></alt-text></graphic></boxed-text><offsets xml_i="33877" xml_f="33878" txt_i="10235" txt_f="10236">
</offsets></p></sec><sec id="onco12239-sec-5312"><p><table-wrap id="nlm-table-wrap-3" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-23" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0004"><alt-text><offsets xml_i="34111" xml_f="34116" txt_i="10238" txt_f="10243">image</offsets></alt-text><permissions><copyright-holder><offsets xml_i="34158" xml_f="34185" txt_i="10243" txt_f="10266">John Wiley &amp; Sons, Ltd.</offsets></copyright-holder></permissions></graphic></table-wrap><offsets xml_i="34241" xml_f="34242" txt_i="10266" txt_f="10267">
</offsets></p></sec><sec id="onco12239-sec-5422"><p><offsets xml_i="34284" xml_f="34285" txt_i="10269" txt_f="10270">
</offsets><boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12239-fig-0005.jpg" position="anchor" id="nlm-graphic-25" specific-use="sourcefile-name" orientation="portrait"><alt-text><offsets xml_i="34508" xml_f="34513" txt_i="10270" txt_f="10275">image</offsets></alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-0014"><title><offsets xml_i="34593" xml_f="34656" txt_i="10277" txt_f="10340">Assessment: Total Patient Population: Progression‐Free Survival</offsets></title><p><offsets xml_i="34667" xml_f="34668" txt_i="10341" txt_f="10342">
</offsets><def-list id="onco12239-lp-0009"><def-item><term id="onco12239-li-0271"><offsets xml_i="34740" xml_f="34767" txt_i="10342" txt_f="10369">Number of patients screened</offsets></term><def id="onco12239-li-0272"><p><offsets xml_i="34805" xml_f="34807" txt_i="10369" txt_f="10371">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0273"><offsets xml_i="34867" xml_f="34894" txt_i="10372" txt_f="10399">Number of patients enrolled</offsets></term><def id="onco12239-li-0274"><p><offsets xml_i="34932" xml_f="34934" txt_i="10399" txt_f="10401">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0275"><offsets xml_i="34994" xml_f="35035" txt_i="10402" txt_f="10443">Number of patients evaluable for toxicity</offsets></term><def id="onco12239-li-0276"><p><offsets xml_i="35073" xml_f="35075" txt_i="10443" txt_f="10445">64</offsets></p></def></def-item><def-item><term id="onco12239-li-0277"><offsets xml_i="35135" xml_f="35176" txt_i="10446" txt_f="10487">Number of patients evaluated for efficacy</offsets></term><def id="onco12239-li-0278"><p><offsets xml_i="35214" xml_f="35216" txt_i="10487" txt_f="10489">66</offsets></p></def></def-item><def-item><term id="onco12239-li-0279"><offsets xml_i="35276" xml_f="35293" txt_i="10490" txt_f="10507">Evaluation method</offsets></term><def id="onco12239-li-0280"><p><offsets xml_i="35331" xml_f="35341" txt_i="10507" txt_f="10517">RECIST 1.1</offsets></p></def></def-item><def-item><term id="onco12239-li-0281"><offsets xml_i="35401" xml_f="35423" txt_i="10518" txt_f="10540">Response assessment CR</offsets></term><def id="onco12239-li-0282"><p><italic><offsets xml_i="35469" xml_f="35470" txt_i="10540" txt_f="10541">n</offsets></italic><offsets xml_i="35479" xml_f="35488" txt_i="10541" txt_f="10550"> = 0 (0%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0283"><offsets xml_i="35548" xml_f="35570" txt_i="10551" txt_f="10573">Response assessment PR</offsets></term><def id="onco12239-li-0284"><p><italic><offsets xml_i="35616" xml_f="35617" txt_i="10573" txt_f="10574">n</offsets></italic><offsets xml_i="35626" xml_f="35637" txt_i="10574" txt_f="10585"> = 12 (18%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0285"><offsets xml_i="35697" xml_f="35719" txt_i="10586" txt_f="10608">Response assessment SD</offsets></term><def id="onco12239-li-0286"><p><italic><offsets xml_i="35765" xml_f="35766" txt_i="10608" txt_f="10609">n</offsets></italic><offsets xml_i="35775" xml_f="35786" txt_i="10609" txt_f="10620"> = 16 (24%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0287"><offsets xml_i="35846" xml_f="35868" txt_i="10621" txt_f="10643">Response assessment PD</offsets></term><def id="onco12239-li-0288"><p><italic><offsets xml_i="35914" xml_f="35915" txt_i="10643" txt_f="10644">n</offsets></italic><offsets xml_i="35924" xml_f="35935" txt_i="10644" txt_f="10655"> = 21 (32%)</offsets></p></def></def-item><def-item><term id="onco12239-li-0289"><offsets xml_i="35995" xml_f="36020" txt_i="10656" txt_f="10681">Response assessment OTHER</offsets></term><def id="onco12239-li-0290"><p><italic><offsets xml_i="36066" xml_f="36067" txt_i="10681" txt_f="10682">n</offsets></italic><offsets xml_i="36076" xml_f="36087" txt_i="10682" txt_f="10693"> = 17 (26%)</offsets></p></def></def-item><def-item><term id="onco12239-li-4219"><offsets xml_i="36147" xml_f="36170" txt_i="10694" txt_f="10717">Kaplan-Meier time units</offsets></term><def id="onco12239-li-4220"><p><offsets xml_i="36208" xml_f="36214" txt_i="10717" txt_f="10723">months</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-2412"><p><offsets xml_i="36288" xml_f="36289" txt_i="10726" txt_f="10727">
</offsets><table-wrap id="nlm-table-wrap-4" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-29" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0005"><alt-text><offsets xml_i="36480" xml_f="36485" txt_i="10727" txt_f="10732">image</offsets></alt-text><permissions><copyright-holder><offsets xml_i="36527" xml_f="36554" txt_i="10732" txt_f="10755">John Wiley &amp; Sons, Ltd.</offsets></copyright-holder></permissions></graphic></table-wrap><offsets xml_i="36610" xml_f="36611" txt_i="10755" txt_f="10756">
</offsets></p></sec><sec id="onco12239-sec-6782"><p><boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12239-fig-0006.jpg" position="anchor" id="nlm-graphic-31" specific-use="sourcefile-name" orientation="portrait"><alt-text><offsets xml_i="36876" xml_f="36881" txt_i="10758" txt_f="10763">image</offsets></alt-text></graphic></boxed-text></p></sec><sec id="onco12239-sec-1014"><title><offsets xml_i="36961" xml_f="36975" txt_i="10765" txt_f="10779">Adverse Events</offsets></title><p><offsets xml_i="36986" xml_f="36987" txt_i="10780" txt_f="10781">
</offsets><table-wrap id="nlm-table-wrap-5" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-35" specific-use="sourcefile-name" xlink:href="onco12239-tbl-0006"><alt-text><offsets xml_i="37178" xml_f="37183" txt_i="10781" txt_f="10786">image</offsets></alt-text><permissions><copyright-holder><offsets xml_i="37225" xml_f="37252" txt_i="10786" txt_f="10809">John Wiley &amp; Sons, Ltd.</offsets></copyright-holder></permissions></graphic></table-wrap><offsets xml_i="37308" xml_f="37309" txt_i="10809" txt_f="10810">
</offsets></p></sec><sec id="onco12239-sec-0015"><title><offsets xml_i="37355" xml_f="37391" txt_i="10812" txt_f="10848">Assessment, Analysis, and Discussion</offsets></title><p><offsets xml_i="37402" xml_f="37403" txt_i="10849" txt_f="10850">
</offsets><def-list id="onco12239-lp-0010"><def-item><term id="onco12239-li-0291"><offsets xml_i="37475" xml_f="37485" txt_i="10850" txt_f="10860">Completion</offsets></term><def id="onco12239-li-0292"><p><offsets xml_i="37523" xml_f="37538" txt_i="10860" txt_f="10875">Study completed</offsets></p></def></def-item><def-item><term id="onco12239-li-0293"><offsets xml_i="37598" xml_f="37631" txt_i="10876" txt_f="10909">Pharmacokinetics/Pharmacodynamics</offsets></term><def id="onco12239-li-0294"><p><offsets xml_i="37669" xml_f="37698" txt_i="10909" txt_f="10938">Correlative endpoints not met</offsets></p></def></def-item><def-item><term id="onco12239-li-0295"><offsets xml_i="37758" xml_f="37783" txt_i="10939" txt_f="10964">Investigator's Assessment</offsets></term><def id="onco12239-li-0296"><p><offsets xml_i="37821" xml_f="37890" txt_i="10964" txt_f="11033">Feasible, possibly effective in patients with high Hsp27 serum levels</offsets></p></def></def-item></def-list></p></sec><sec id="onco12239-sec-0016"><p><offsets xml_i="37964" xml_f="38105" txt_i="11036" txt_f="11177">Pancreatic adenocarcinoma is expected to rise to the second leading cause of cancer‐related mortality in the U.S. by the end of this decade [</offsets><xref rid="onco12239-bib-0009" ref-type="ref"><offsets xml_i="38151" xml_f="38152" txt_i="11177" txt_f="11178">9</offsets></xref><offsets xml_i="38159" xml_f="38392" txt_i="11178" txt_f="11411">]. Systemic therapy represents the mainstay of treatment for patients with advanced or metastatic disease, for whom two combination chemotherapy regimens have emerged as front‐line standards of care: gemcitabine plus nab‐paclitaxel [</offsets><xref rid="onco12239-bib-0008" ref-type="ref"><offsets xml_i="38438" xml_f="38439" txt_i="11411" txt_f="11412">8</offsets></xref><offsets xml_i="38446" xml_f="38523" txt_i="11412" txt_f="11489">], and FOLFIRINOX (5‐fluorouracil, leucovorin, irinotecan, and oxaliplatin) [</offsets><xref rid="onco12239-bib-0010" ref-type="ref"><offsets xml_i="38569" xml_f="38571" txt_i="11489" txt_f="11491">10</offsets></xref><offsets xml_i="38578" xml_f="39087" txt_i="11491" txt_f="12000">]. However, despite these recent improvements in available cytotoxic therapies, overall prognosis in this disease remains very poor; for example, in the phase III MPACT trial leading to the approval of nab‐paclitaxel for metastatic pancreatic cancer, the median survival for patients receiving the combination of gemcitabine plus nab‐paclitaxel was only 8.5 months, representing a statistically significant but relatively modest absolute improvement of 1.8 months when compared with single‐agent gemcitabine [</offsets><xref rid="onco12239-bib-0008" ref-type="ref"><offsets xml_i="39133" xml_f="39134" txt_i="12000" txt_f="12001">8</offsets></xref><offsets xml_i="39141" xml_f="39226" txt_i="12001" txt_f="12086">]. Clearly, novel drugs with unique mechanisms of action warrant further exploration.</offsets></p><p><offsets xml_i="39233" xml_f="39970" txt_i="12087" txt_f="12824">Molecularly targeted therapies that have been approved for use in clinical oncology include monoclonal antibodies and small molecule inhibitors, particularly tyrosine kinase inhibitors. Unfortunately, many potential therapeutic targets are not amenable to these specific pharmacologic approaches, highlighting the importance of developing alternative strategies, including agents that can disrupt these targets at the gene expression level. Antisense oligonucleotides (ASOs), which are chemically modified stretches of single‐strand DNA complementary to the mRNA regions of a target gene that inhibit translation by forming RNA/DNA duplexes, represent one such approach to specifically prevent translation of functionally relevant genes.</offsets></p><p><offsets xml_i="39977" xml_f="40775" txt_i="12825" txt_f="13623">Apatorsen, a 2’‐methoxyethyl oligonucleotide with phosphorothiolated internucleotide linkages, is designed to bind to heat shock protein 27 (Hsp27) mRNA and prevent translation into a functional protein. Targeting this specific heat shock protein represents an attractive therapeutic option, because Hsp27 can potentially affect multiple pathways implicated in cancer progression and resistance, as opposed to targeting a single pathway, a strategy that might have limited benefits in the face of the redundant signaling pathways and significant tumor heterogeneity. For example, overexpression of Hsp27 in cancer cells is induced by cytotoxic chemotherapy, as well as other cell stressors including hyperthermia, oxidative stress, and radiation, resulting in cytoprotection against these insults [</offsets><xref rid="onco12239-bib-0001" ref-type="ref"><offsets xml_i="40821" xml_f="40822" txt_i="13623" txt_f="13624">1</offsets></xref><offsets xml_i="40829" xml_f="40833" txt_i="13624" txt_f="13628">], [</offsets><xref rid="onco12239-bib-0002" ref-type="ref"><offsets xml_i="40879" xml_f="40880" txt_i="13628" txt_f="13629">2</offsets></xref><offsets xml_i="40887" xml_f="41055" txt_i="13629" txt_f="13797">]. Furthermore, Hsp27 serves to stabilize mutated or inappropriately activated oncoproteins that contribute to the initiation, growth, and metastasis of human cancers [</offsets><xref rid="onco12239-bib-0002" ref-type="ref"><offsets xml_i="41101" xml_f="41102" txt_i="13797" txt_f="13798">2</offsets></xref><offsets xml_i="41109" xml_f="41113" txt_i="13798" txt_f="13802">], [</offsets><xref rid="onco12239-bib-0011" ref-type="ref"><offsets xml_i="41159" xml_f="41161" txt_i="13802" txt_f="13804">11</offsets></xref><offsets xml_i="41168" xml_f="41170" txt_i="13804" txt_f="13806">].</offsets></p><p><offsets xml_i="41177" xml_f="41477" txt_i="13807" txt_f="14107">The phase I dose‐escalation study of apatorsen in patients with castration‐resistant prostate cancer and other advanced cancers showed evidence of monotherapy activity as demonstrated by decline in tumor markers and circulating tumor cells, as well as stable measurable disease in 12 of 42 patients [</offsets><xref rid="onco12239-bib-0012" ref-type="ref"><offsets xml_i="41523" xml_f="41525" txt_i="14107" txt_f="14109">12</offsets></xref><offsets xml_i="41532" xml_f="41699" txt_i="14109" txt_f="14276">]. Further evaluation of apatorsen has been pursued in combination with chemotherapeutic agents in clinical trials specific to non‐small cell lung and bladder cancer [</offsets><xref rid="onco12239-bib-0013" ref-type="ref"><offsets xml_i="41745" xml_f="41747" txt_i="14276" txt_f="14278">13</offsets></xref><offsets xml_i="41754" xml_f="41758" txt_i="14278" txt_f="14282">], [</offsets><xref rid="onco12239-bib-0014" ref-type="ref"><offsets xml_i="41804" xml_f="41806" txt_i="14282" txt_f="14284">14</offsets></xref><offsets xml_i="41813" xml_f="41815" txt_i="14284" txt_f="14286">].</offsets></p><p><offsets xml_i="41822" xml_f="42042" txt_i="14287" txt_f="14507">Pancreatic adenocarcinomas show higher levels of Hsp27 expression when compared with healthy pancreatic tissue, and the protein can also be detected with high sensitivity in the serum of patients with pancreatic cancer [</offsets><xref rid="onco12239-bib-0003" ref-type="ref"><offsets xml_i="42088" xml_f="42089" txt_i="14507" txt_f="14508">3</offsets></xref><offsets xml_i="42096" xml_f="42241" txt_i="14508" txt_f="14653">]. Preclinical studies additionally show that Hsp27 expression may play a role in the resistance of pancreatic cancer cell lines to gemcitabine [</offsets><xref rid="onco12239-bib-0004" ref-type="ref"><offsets xml_i="42287" xml_f="42288" txt_i="14653" txt_f="14654">4</offsets></xref><offsets xml_i="42295" xml_f="42299" txt_i="14654" txt_f="14658">], [</offsets><xref rid="onco12239-bib-0005" ref-type="ref"><offsets xml_i="42345" xml_f="42346" txt_i="14658" txt_f="14659">5</offsets></xref><offsets xml_i="42353" xml_f="42357" txt_i="14659" txt_f="14663">], [</offsets><xref rid="onco12239-bib-0006" ref-type="ref"><offsets xml_i="42403" xml_f="42404" txt_i="14663" txt_f="14664">6</offsets></xref><offsets xml_i="42411" xml_f="43552" txt_i="14664" txt_f="15805">]. On these bases, the current study was designed to compare the safety and efficacy of gemcitabine and nab‐paclitaxel in combination with either apatorsen or placebo in the first‐line setting for patients with metastatic pancreatic cancer. However, we did not observe any improvement in clinical outcomes in the intent‐to‐treat population in this trial; indeed, patients on the apatorsen arm fared numerically worse in terms of both PFS and OS when compared with patients on the placebo control arm, although these differences were not statistically significant. The only subgroup for whom a potential benefit of apatorsen could be identified was those patients with high serum levels of Hsp27, a marker that portended a very poor prognosis overall. However, the number of subjects who fit into this category was too small, representing only 14% of the entire study population, to draw any definitive conclusions. Further studies, either prospectively designed trials or retrospective analyses of available clinically annotated samples, will be required to assess whether Hsp27 truly represents an adverse prognostic marker in this disease.</offsets></p><p><offsets xml_i="43559" xml_f="43792" txt_i="15806" txt_f="16039">Several additional points are worth noting. First, the clinical outcomes for patients on both arms of this study were considerably inferior to those observed on the gemcitabine plus nab‐paclitaxel arm from the phase III MPACT trial [</offsets><xref rid="onco12239-bib-0008" ref-type="ref"><offsets xml_i="43838" xml_f="43839" txt_i="16039" txt_f="16040">8</offsets></xref><offsets xml_i="43846" xml_f="44918" txt_i="16040" txt_f="17112">], in which patients achieved a median OS and PFS of 8.5 and 5.5 months, respectively. It is unclear why subjects on the current study fared so poorly, given similar demographics to the MPACT study; nevertheless, it seems fairly unlikely that a benefit from apatorsen would somehow be unmasked even if patients had achieved outcomes that more similarly matched those of the MPACT trial. Furthermore, because this study did not mandate pretreatment collection of tumor specimens, putative tissue‐based predictive markers of apatorsen sensitivity could not be assessed, nor could the pharmacodynamic effects of this agent given the absence of requiring on‐treatment tumor biopsies. No consistent trend was identified on serial serum Hsp27 measurements in responders versus nonresponders (data not shown). This lack of robust correlative data represents a major limitation of our study and highlights one of the major ongoing challenges in pancreatic cancer trial design in general, especially when trying to confirm the putative mechanism of action of novel targeted agents.</offsets></p><p><offsets xml_i="44925" xml_f="45793" txt_i="17113" txt_f="17981">In conclusion, the addition of apatorsen to a standard combination chemotherapy regimen in the first‐line setting did not result in improved survival or other clinically relevant endpoints in patients with metastatic pancreatic cancer. Further studies of this agent in unselected patients do not appear to be indicated, although the findings from this trial do hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation. If ASO technologies targeting this and other cancer‐related genes continue to be pursued in pancreatic cancer, they should ideally be evaluated in the context of trials that mandate serial collection of both tumor and blood samples to look for predictive markers and pharmacodynamic markers of response, notwithstanding the clinical and logistic hurdles these may present in this patient population.</offsets></p></sec></body><back><ack id="onco12239-sec-0017"><title>Acknowledgments</title><p>This work was supported in part by a grant from OncoGenex Pharmaceuticals, Inc.</p></ack><fn-group><fn fn-type="other" id="onco12239-note-1201"><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01844817">NCT01844817</ext-link></p><p><bold>Sponsor</bold>: Sarah Cannon Research Institute</p><p><bold>Principal Investigators</bold>: Andrew H. Ko, Johanna C. Bendell</p><p><bold>IRB Approved</bold>: Yes</p></fn><fn id="onco12239-note-4392"><p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here to access other published clinical trials</ext-link>.</p></fn><fn id="onco12239-note-0102"><p>See the related commentary on page <ext-link ext-link-type="doi" xlink:href="10.1634/theoncologist.2017-0453">1424</ext-link>.</p></fn></fn-group><sec id="onco12239-sec-0018" sec-type="disclosure"><title>Disclosures</title><p><bold>Andrew H. Ko</bold>: Seattle Genetics, New Beta Innovations (C/A), Merck, Bristol‐Myers Squibb, Abgenomics, Prism Bio Ltd, Merrimack, Halozyme, Celgene, Roche/Genentech (RF); <bold>David M. Waterhouse</bold>: Bristol‐Myers Squibb, ABBVie (H). The other authors indicated no financial relationships.</p><p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p></sec><ref-list content-type="cited-references"><title>References</title><ref id="onco12239-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="onco12239-cit-0001">
<string-name><surname>Garrido</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Brunet</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Didelot</surname>
<given-names>C</given-names></string-name> et al. <article-title>Heat shock proteins 27 and 70: Anti‐apoptotic proteins with tumorigenic properties</article-title>. <source>Cell Cycle</source>
<year>2006</year>;<volume>5</volume>:<fpage>2592</fpage>–<lpage>2601</lpage>.
<pub-id pub-id-type="pmid">17106261</pub-id></mixed-citation></ref><ref id="onco12239-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="onco12239-cit-0002">
<string-name><surname>Ciocca</surname>
<given-names>DR</given-names></string-name>, 
<string-name><surname>Calderwood</surname>
<given-names>SK.</given-names></string-name>
<article-title>Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications</article-title>. <source>Cell Stress Chaperones</source>
<year>2005</year>;<volume>10</volume>:<fpage>86</fpage>–<lpage>103</lpage>.
<pub-id pub-id-type="pmid">16038406</pub-id></mixed-citation></ref><ref id="onco12239-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="onco12239-cit-0003">
<string-name><surname>Melle</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Ernst</surname>
<given-names>G</given-names></string-name>, 
<string-name><surname>Escher</surname>
<given-names>N</given-names></string-name> et al. <article-title>Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker</article-title>. <source>Clin Chem</source>
<year>2007</year>;<volume>53</volume>:<fpage>629</fpage>–<lpage>635</lpage>.
<pub-id pub-id-type="pmid">17303689</pub-id></mixed-citation></ref><ref id="onco12239-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="onco12239-cit-0004">
<string-name><surname>Kuramitsu</surname>
<given-names>Y</given-names></string-name>, 
<string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, 
<string-name><surname>Taba</surname>
<given-names>K</given-names></string-name> et al. <article-title>Heat‐shock protein 27 plays the key role in gemcitabine‐resistance of pancreatic cancer cells</article-title>. <source>Anticancer Res</source>
<year>2012</year>;<volume>32</volume>:<fpage>2295</fpage>–<lpage>2299</lpage>.
<pub-id pub-id-type="pmid">22641665</pub-id></mixed-citation></ref><ref id="onco12239-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="onco12239-cit-0005">
<string-name><surname>Zhang</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Zhang</surname>
<given-names>XQ</given-names></string-name>, 
<string-name><surname>Huang</surname>
<given-names>SL</given-names></string-name> et al. <article-title>The effects of HSP27 on gemcitabine‐resistant pancreatic cancer cell line through snail</article-title>. <source>Pancreas</source>
<year>2015</year>;<volume>44</volume>:<fpage>1121</fpage>–<lpage>1129</lpage>.
<pub-id pub-id-type="pmid">26348464</pub-id></mixed-citation></ref><ref id="onco12239-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="onco12239-cit-0006">
<string-name><surname>Guo</surname>
<given-names>Y</given-names></string-name>, 
<string-name><surname>Ziesch</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Hocke</surname>
<given-names>S</given-names></string-name> et al. <article-title>Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S‐phase arrest and apoptosis</article-title>. <source>J Cell Mol Med</source>
<year>2015</year>;<volume>19</volume>:<fpage>340</fpage>–<lpage>350</lpage>.
<pub-id pub-id-type="pmid">25331547</pub-id></mixed-citation></ref><ref id="onco12239-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="onco12239-cit-0007">
<string-name><surname>Kamada</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>So</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Muramaki</surname>
<given-names>M</given-names></string-name> et al. <article-title>Hsp27 knockdown using nucleotide‐based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells</article-title>. <source>Mol Cancer Ther</source>
<year>2007</year>;<volume>6</volume>:<fpage>299</fpage>–<lpage>308</lpage>.
<pub-id pub-id-type="pmid">17218637</pub-id></mixed-citation></ref><ref id="onco12239-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="onco12239-cit-0008">
<string-name><surname>Von Hoff</surname>
<given-names>DD</given-names></string-name>, 
<string-name><surname>Ervin</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Arena</surname>
<given-names>FP</given-names></string-name> et al. <article-title>Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine</article-title>. <source>N Engl J Med</source>
<year>2013</year>;<volume>369</volume>:<fpage>1691</fpage>–<lpage>1703</lpage>.
<pub-id pub-id-type="pmid">24131140</pub-id></mixed-citation></ref><ref id="onco12239-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="onco12239-cit-0009">
<string-name><surname>Rahib</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Smith</surname>
<given-names>BD</given-names></string-name>, 
<string-name><surname>Aizenberg</surname>
<given-names>R</given-names></string-name> et al. <article-title>Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States</article-title>. <source>Cancer Res</source>
<year>2014</year>;<volume>74</volume>:<fpage>2913</fpage>–<lpage>2921</lpage>.
<pub-id pub-id-type="pmid">24840647</pub-id></mixed-citation></ref><ref id="onco12239-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="onco12239-cit-0010">
<string-name><surname>Conroy</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Desseigne</surname>
<given-names>F</given-names></string-name>, 
<string-name><surname>Ychou</surname>
<given-names>M</given-names></string-name> et al. <article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>. <source>N Engl J Med</source>
<year>2011</year>;<volume>364</volume>:<fpage>1817</fpage>–<lpage>1825</lpage>.
<pub-id pub-id-type="pmid">21561347</pub-id></mixed-citation></ref><ref id="onco12239-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="onco12239-cit-0011">
<string-name><surname>Acunzo</surname>
<given-names>J</given-names></string-name>, 
<string-name><surname>Andrieu</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Baylot</surname>
<given-names>V</given-names></string-name> et al. <article-title>Hsp27 as a therapeutic target in cancers</article-title>. <source>Curr Drug Targets</source>
<year>2014</year>;<volume>15</volume>:<fpage>423</fpage>–<lpage>431</lpage>.
<pub-id pub-id-type="pmid">24138636</pub-id></mixed-citation></ref><ref id="onco12239-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="onco12239-cit-0012">
<string-name><surname>Chi</surname>
<given-names>KN</given-names></string-name>, 
<string-name><surname>Yu</surname>
<given-names>EY</given-names></string-name>, 
<string-name><surname>Jacobs</surname>
<given-names>C</given-names></string-name> et al. <article-title>A phase I dose‐escalation study of apatorsen (OGX‐427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration‐resistant prostate cancer and other advanced cancers</article-title>. <source>Ann Oncol</source>
<year>2016</year>;<volume>27</volume>:<fpage>1116</fpage>–<lpage>1122</lpage>.
<pub-id pub-id-type="pmid">27022067</pub-id></mixed-citation></ref><ref id="onco12239-bib-0013"><label>13</label><mixed-citation publication-type="book" id="onco12239-cit-0013">
<string-name><surname>Choueiri</surname>
<given-names>TK</given-names></string-name>, 
<string-name><surname>Hahn</surname>
<given-names>NM</given-names></string-name>, 
<string-name><surname>Pal</surname>
<given-names>SK</given-names></string-name> et al. <chapter-title>The Borealis‐2 clinical trial: A randomized phase 2 study of OGX‐427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer</chapter-title>
<source>J Clin Oncol</source>
<year>2014</year>;<publisher-name>32</publisher-name>(suppl):<fpage>TPS4593a</fpage>.
</mixed-citation></ref><ref id="onco12239-bib-0014"><label>14</label><mixed-citation publication-type="book" id="onco12239-cit-0014">
<string-name><surname>Spigel</surname>
<given-names>DR</given-names></string-name>, 
<string-name><surname>Burris</surname>
<given-names>HA</given-names></string-name>, 
<string-name><surname>Greco</surname>
<given-names>FA</given-names></string-name> et al. <chapter-title>Double‐blind randomized phase II trial of carboplatin and pemetrexed with or without OGX‐427 in patients with previously untreated stage IV non‐squamous non‐small‐cell lung cancer (NSCLC): The Spruce Clinical Trial</chapter-title>
<source>J Clin Oncol</source>
<year>2013</year>;31(suppl):<fpage>TPS8120a</fpage>.
</mixed-citation></ref></ref-list></back></article>